Buy Or Sell Opportunity • Jul 08
Now 26% overvalued after recent price rise Over the last 90 days, the stock has risen 85% to ₹1,000. The fair value is estimated to be ₹793, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.2% over the last 3 years. Earnings per share has declined by 27%. Revenue is forecast to grow by 59% in a year. Earnings are forecast to grow by 604% in the next year. Buy Or Sell Opportunity • Jun 16
Now 26% overvalued after recent price rise Over the last 90 days, the stock has risen 94% to ₹1,044. The fair value is estimated to be ₹831, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.2% over the last 3 years. Earnings per share has declined by 27%. Revenue is forecast to grow by 59% in a year. Earnings are forecast to grow by 746% in the next year. New Risk • May 26
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 20% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (20% accrual ratio). Minor Risk Profit margins are more than 30% lower than last year (2.4% net profit margin). Reported Earnings • May 26
Full year 2026 earnings: EPS misses analyst expectations Full year 2026 results: EPS: ₹4.05 (down from ₹19.65 in FY 2025). Revenue: ₹8.47b (down 8.2% from FY 2025). Net income: ₹205.5m (down 79% from FY 2025). Profit margin: 2.4% (down from 11% in FY 2025). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 51%. Revenue is forecast to grow 41% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has fallen by 27% per year but the company’s share price has increased by 20% per year, which means it is well ahead of earnings. Ankündigung • May 19
Orchid Pharma Limited to Report Q4, 2026 Results on May 25, 2026 Orchid Pharma Limited announced that they will report Q4, 2026 results on May 25, 2026 Reported Earnings • Feb 12
Third quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behind Third quarter 2026 results: ₹2.49 loss per share (down from ₹4.10 profit in 3Q 2025). Revenue: ₹2.13b (down 2.1% from 3Q 2025). Net loss: ₹126.1m (down 161% from profit in 3Q 2025). Revenue exceeded analyst estimates by 16%. Earnings per share (EPS) missed analyst estimates. Revenue is forecast to grow 45% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has increased by 18% per year, which means it is tracking significantly ahead of earnings growth. Ankündigung • Feb 06
Orchid Pharma Limited to Report Q3, 2026 Results on Feb 11, 2026 Orchid Pharma Limited announced that they will report Q3, 2026 results on Feb 11, 2026 New Risk • Nov 12
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 6.3% Last year net profit margin: 13% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (22% accrual ratio). Minor Risk Profit margins are more than 30% lower than last year (6.3% net profit margin). Reported Earnings • Nov 12
Second quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behind Second quarter 2026 results: ₹1.13 loss per share (down from ₹5.37 profit in 2Q 2025). Revenue: ₹2.04b (down 8.3% from 2Q 2025). Net loss: ₹57.2m (down 121% from profit in 2Q 2025). Revenue exceeded analyst estimates by 5.3%. Earnings per share (EPS) missed analyst estimates. Revenue is forecast to grow 38% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has only increased by 26% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Nov 06
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹831, the stock trades at a forward P/E ratio of 42x. Average forward P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 104% over the past three years. Ankündigung • Nov 05
Orchid Pharma Limited to Report Q2, 2026 Results on Nov 11, 2025 Orchid Pharma Limited announced that they will report Q2, 2026 results at 12:08 PM, Indian Standard Time on Nov 11, 2025 Price Target Changed • Aug 16
Price target decreased by 8.8% to ₹913 Down from ₹1,001, the current price target is an average from 3 analysts. New target price is 22% above last closing price of ₹748. Stock is down 46% over the past year. The company is forecast to post earnings per share of ₹15.35 for next year compared to ₹19.65 last year. Reported Earnings • Aug 13
First quarter 2026 earnings released: EPS: ₹2.94 (vs ₹5.79 in 1Q 2025) First quarter 2026 results: EPS: ₹2.94 (down from ₹5.79 in 1Q 2025). Revenue: ₹1.84b (down 25% from 1Q 2025). Net income: ₹149.1m (down 49% from 1Q 2025). Profit margin: 8.1% (down from 12% in 1Q 2025). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 35% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has only increased by 35% per year, which means it is significantly lagging earnings growth. Ankündigung • Aug 12
Orchid Pharma Limited, Annual General Meeting, Sep 20, 2025 Orchid Pharma Limited, Annual General Meeting, Sep 20, 2025. Ankündigung • Aug 06
Orchid Pharma Limited to Report Q1, 2026 Results on Aug 12, 2025 Orchid Pharma Limited announced that they will report Q1, 2026 results on Aug 12, 2025 Ankündigung • Jul 31
Orchid Pharma Limited (NSEI:ORCHPHARMA) proposed to acquire all assets of Allecra Therapeutics GmbH and Allecra Therapeutics SAS. Orchid Pharma Limited (NSEI:ORCHPHARMA) proposed to acquire all assets of Allecra Therapeutics GmbH and Allecra Therapeutics SAS on July 30, 2025. Reported Earnings • May 28
Full year 2025 earnings: EPS exceeds analyst expectations Full year 2025 results: EPS: ₹19.65 (up from ₹19.06 in FY 2024). Revenue: ₹9.49b (up 16% from FY 2024). Net income: ₹996.6m (up 8.1% from FY 2024). Profit margin: 11% (in line with FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 3.6%. Revenue is forecast to grow 26% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 76% per year but the company’s share price has only increased by 31% per year, which means it is significantly lagging earnings growth. Price Target Changed • May 27
Price target decreased by 30% to ₹1,001 Down from ₹1,438, the current price target is an average from 3 analysts. New target price is 42% above last closing price of ₹704. Stock is down 31% over the past year. The company is forecast to post earnings per share of ₹18.97 for next year compared to ₹19.06 last year. Valuation Update With 7 Day Price Move • Mar 14
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to ₹795, the stock trades at a forward P/E ratio of 30x. Average forward P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 181% over the past three years. New Risk • Feb 13
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Reported Earnings • Feb 13
Third quarter 2025 earnings released: EPS: ₹4.10 (vs ₹6.18 in 3Q 2024) Third quarter 2025 results: EPS: ₹4.10 (down from ₹6.18 in 3Q 2024). Revenue: ₹2.26b (up 2.4% from 3Q 2024). Net income: ₹207.8m (down 29% from 3Q 2024). Profit margin: 9.2% (down from 13% in 3Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 39% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 90% per year but the company’s share price has only increased by 51% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Feb 12
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to ₹1,234, the stock trades at a forward P/E ratio of 37x. Average forward P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 305% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₹835 per share. Ankündigung • Feb 07
Orchid Pharma Limited to Report Q3, 2025 Results on Feb 12, 2025 Orchid Pharma Limited announced that they will report Q3, 2025 results on Feb 12, 2025 Reported Earnings • Nov 12
Second quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind Second quarter 2025 results: EPS: ₹5.37 (up from ₹4.30 in 2Q 2024). Revenue: ₹2.30b (up 16% from 2Q 2024). Net income: ₹272.4m (up 38% from 2Q 2024). Profit margin: 12% (up from 10.0% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 4.6%. Earnings per share (EPS) exceeded analyst estimates by 34%. Revenue is forecast to grow 34% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 103% per year but the company’s share price has only increased by 52% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Nov 01
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹1,456, the stock trades at a forward P/E ratio of 46x. Average forward P/E is 34x in the Pharmaceuticals industry in India. Total returns to shareholders of 257% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₹2,140 per share. Reported Earnings • Aug 13
First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind First quarter 2025 results: EPS: ₹5.79 (up from ₹1.85 in 1Q 2024). Revenue: ₹2.52b (up 38% from 1Q 2024). Net income: ₹293.5m (up 212% from 1Q 2024). Profit margin: 12% (up from 5.1% in 1Q 2024). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 8.2%. Earnings per share (EPS) missed analyst estimates by 16%. Revenue is forecast to grow 32% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 109% per year but the company’s share price has only increased by 52% per year, which means it is significantly lagging earnings growth. Buy Or Sell Opportunity • Aug 13
Now 21% undervalued Over the last 90 days, the stock has risen 28% to ₹1,406. The fair value is estimated to be ₹1,772, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 23% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 89% in 2 years. Earnings are forecast to grow by 149% in the next 2 years. Ankündigung • Jul 23
Orchid Pharma Limited, Annual General Meeting, Aug 21, 2024 Orchid Pharma Limited, Annual General Meeting, Aug 21, 2024, at 11:30 Indian Standard Time. Valuation Update With 7 Day Price Move • Jul 22
Investor sentiment improves as stock rises 24% After last week's 24% share price gain to ₹1,387, the stock trades at a forward P/E ratio of 47x. Average forward P/E is 31x in the Pharmaceuticals industry in India. Total returns to shareholders of 177% over the past three years. Ankündigung • Jun 08
Orchid Pharma Receives DCGI Approval for Its First Invented and Made-In-India Antibiotic Drug Combination of Cefepime and Enmetazobactam Orchid Pharma has received Drugs Controller General of India (DCGI) approval for the manufacturing and marketing of its invented New Chemical Entity Active Pharmaceutical Ingredient (API), Enmetazobactam. DCGI has also granted permission to manufacture and market Finished Dosage Form (FDF) of Cefepime and Enmetazobactam as a dry powder injectable. This formulation is indicated for the treatment of complicated Urinary Tract Infections (cUTI) including acute Pyelonephritis, Hospital- Acquired Pneumonia (HAP) including Ventilator-associated pneumonia (VAP), and Bacteremia when it is associated or suspected to be associated with either complicated urinary tract infections or hospital-acquired pneumonia. With this approval, Orchid Pharma intends to improve the treatment landscape for serious infections in India, providing patients with access to advanced and effective therapy options. The company looks forward to the successful launch and distribution of Enmetazobactam and its combination with Cefepime for enhancing the treatment landscape for severe infections in India. Ankündigung • May 24
Orchid Pharma Limited Appoints Shubha Singh as Additional Director Orchid Pharma Limited announced that at the board meeting held on May 23, 2024, the company approved the appointment of Ms. Shubha Singh as an additional director in the category of Non - Executive Independent Director, effective May 23, 2024. Honored with the Best Non-Executive Director Award in Listed Company category at MMB Iconic Women Directors of India, 2023 conclave held on 15th December, 2023 at BSE Convention center, Mumbai. Mrs.Smriti Irani and Dr. Kiran Bedi presided over the conclave. Featured on coverpage of Boardstewardship magazine in Women's Day Special edition March, 2024 and also my thoughts on ESG published in the same edition. Awarded the Distinguished Alumni Award 2024 for Corporate Excellence in Finance category by IMT CDL at Alumni meet held on 11th February, 2024. Company Secretary from ICSI, New Delhi since 2003. Additionally, Chartered Financial Analyst (CFA) from ICFAI, Hyderabad since 2002, Post Graduate Diploma in Financial Analysis from ICFAI, Hyderabad since 2002, MBA (International Business) from IMT, Ghaziabad since 2013 and Law graduate from Faculty of Law. B.Com (Hons) from Hansraj College, Delhi University in 1996 and schooling from Delhi Public School, Noida. An Independent/Non-Executive Director in 2 listed and 4 unlisted Companies. Chairperson and Member of various Board Committees. 23 years of experience in secretarial, finance and legal functions, primarily in Listed Companies. Managing and advising various corporates in legal and secretarial matters with expertise in Corporate and general laws, litigation civil and criminal, strategizing, Contracting, Agreements, Corporate Governance, re-structuring, revenue modelling, fund raising. Ankündigung • May 18
Orchid Pharma Limited to Report Q4, 2024 Results on May 23, 2024 Orchid Pharma Limited announced that they will report Q4, 2024 results on May 23, 2024 Buy Or Sell Opportunity • May 08
Now 25% overvalued after recent price rise Over the last 90 days, the stock has risen 17% to ₹1,032. The fair value is estimated to be ₹829, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 22% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 89% in 2 years. Earnings are forecast to grow by 82% in the next 2 years. Ankündigung • Apr 12
Orchid Pharma Limited Announces Resignation of Mudit Tandon as Independent Director Orchid Pharma Limited announced resignation of Mr. Mudit Tandon as Independent Director of the company with effect from close of business hours of April 12, 2024, due to other commitments and personal reasons. Buy Or Sell Opportunity • Mar 18
Now 25% overvalued after recent price rise Over the last 90 days, the stock has risen 45% to ₹1,030. The fair value is estimated to be ₹824, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 22% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 89% in 2 years. Earnings are forecast to grow by 82% in the next 2 years. Valuation Update With 7 Day Price Move • Feb 15
Investor sentiment improves as stock rises 27% After last week's 27% share price gain to ₹1,115, the stock trades at a forward P/E ratio of 44x. Average forward P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 69% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₹828 per share. Buy Or Sell Opportunity • Feb 12
Now 29% overvalued after recent price rise Over the last 90 days, the stock has risen 87% to ₹1,016. The fair value is estimated to be ₹787, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 22% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 73% in 2 years. Earnings are forecast to grow by 62% in the next 2 years. Reported Earnings • Feb 09
Third quarter 2024 earnings: EPS and revenues exceed analyst expectations Third quarter 2024 results: EPS: ₹6.18 (up from ₹1.86 in 3Q 2023). Revenue: ₹2.28b (up 43% from 3Q 2023). Net income: ₹294.3m (up 288% from 3Q 2023). Profit margin: 13% (up from 4.7% in 3Q 2023). Revenue exceeded analyst estimates by 5.1%. Earnings per share (EPS) also surpassed analyst estimates by 54%. Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in India. Over the last 3 years on average, earnings per share has increased by 110% per year but the company’s share price has only increased by 23% per year, which means it is significantly lagging earnings growth. Ankündigung • Feb 03
Orchid Pharma Limited to Report Q3, 2024 Results on Feb 08, 2024 Orchid Pharma Limited announced that they will report Q3, 2024 results on Feb 08, 2024 Ankündigung • Jan 30
European Medicines Agency Grants Approval for Orchid Pharma's 'Exblifep' Orchid Pharma has achieved a significant breakthrough with its antibiotic invention, 'Exblifeb,' which incorporates Enmetazobactam, the first completely invented-in-India Beta Lactamase Inhibitor. This pioneering drug recently received the European Medicines Agency's (EMA) recommendation for marketing authorization, marking the first instance of an Indian-invented drug reaching this stage of clinical development. Designed to address the global challenge of An -Microbial Resistance (AMR), 'Exblifeb' demonstrates remarkable efficacy in treating complicated Urinary Tract Infections (cUTI), pneumonia, and bacteremia caused by Extended Spectrum Beta-lactamase producing pathogens. During clinical trials, 'Exblifeb' exhibited superior performance compared to the current go-to drug, Piperacillin + Tazobactam. It is positioned as a potent, cost-effective, and Carbapenem-sparing therapy, offering a viable solution in the fight against rising AMR. This milestone not only positions 'Exblifeb' as a front-runner in combating AMR but also underscores the urgent need for effective solutions. According to the Global Burden of Disease Study, infections caused by an microbial-resistant bacteria led to the direct death of 1.27 million people in 2019. 'Exblifeb,' with its unique Indian origin and superior clinical performance, has the potential to become a standard of care worldwide in addressing this global health crisis. Enmetazobactam was invented in India by Orchid and then out-licensed to Allecra Therapeutics for further development. Valuation Update With 7 Day Price Move • Jan 30
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₹859, the stock trades at a forward P/E ratio of 36x. Average forward P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 134% over the past three years. Ankündigung • Dec 17
Orchid Pharma Limited Appoints Kapil Dayya as Company Secretary & Compliance Officer Orchid Pharma Limited announced that the Board of Directors of the Company, on the recommendation of Nomination and Remuneration Committee, appointed Mr. Kapil Dayya, a Fellow Member of Institute of Company Secretaries of India, as the Company Secretary & Compliance officer, designated as the Key Managerial Personnel of the Company from December 16, 2023. Mr. Kapil Dayya is an Fellow member of the Institute of Company Secretaries of India, who completed his schooling from St. Xavier Senior Secondary School and holds degree in Master of Commerce. He possess requisite qualifications and skills and good knowledge of Company Law, SEBI Regulations etc. and have an experience of more than 10 Years as the Company Secretary of various esteemed organizations. Ankündigung • Dec 14
Orchid Pharma Limited Announces Resignation of Marina Peter as Company Secretary and Compliance Officer Orchid Pharma Limited announced that Ms. Marina Peter has resigned from the position of Company Secretary and Compliance officer of the Company with effect from December 12, 2023. Reported Earnings • Nov 05
Second quarter 2024 earnings released: EPS: ₹4.30 (vs ₹1.32 loss in 2Q 2023) Second quarter 2024 results: EPS: ₹4.30 (up from ₹1.32 loss in 2Q 2023). Revenue: ₹1.99b (up 20% from 2Q 2023). Net income: ₹198.0m (up ₹252.0m from 2Q 2023). Profit margin: 10.0% (up from net loss in 2Q 2023). Over the last 3 years on average, earnings per share has increased by 97% per year but the company’s share price has increased by 187% per year, which means it is tracking significantly ahead of earnings growth. Ankündigung • Oct 29
Orchid Pharma Limited to Report Q2, 2024 Results on Nov 04, 2023 Orchid Pharma Limited announced that they will report Q2, 2024 results on Nov 04, 2023 Ankündigung • Oct 21
Orchid Pharma Limited Approves the Appointment of Mr. Arjun Dhanuka as Additional Director (In Capacity of Non-Executive & Non-Independent) Orchid Pharma Limited approved the appointment of Mr. Arjun Dhanuka (DIN: 00454689) as Additional Director (in capacity of Non-Executive & Non-Independent), liable to retire by rotation and who shall hold office till the next general meeting or three months from the date of appointment, whichever is earlier. Date of Appointment: October 20, 2023. Mr. Arjun Dhanuka started his career with Dhanuka Laboratories Limited in September 2010. From 2010-2013 his role comprised of managing all the purchase decisions of the company. He graduated from Delhi University and is a now Whole Time Director at Dhanuka Laboratories Limited. In 2013, he started working with operations team of Synmedic Laboratories. After gaining relevant experience, he is presently supervising and is responsible for majority of operations at Synmedic Laboratories since 2020. He strives in Business development and strategy building. Mr. Dhanuka is young and dynamic person with an experience of more than a decade in the Pharmaceuticals Sector. Ankündigung • Aug 05
Orchid Pharma Limited to Report Q1, 2024 Results on Aug 10, 2023 Orchid Pharma Limited announced that they will report Q1, 2024 results on Aug 10, 2023 Reported Earnings • Jul 21
Full year 2023 earnings released: EPS: ₹13.01 (vs ₹14.80 loss in FY 2022) Full year 2023 results: EPS: ₹13.01 (up from ₹14.80 loss in FY 2022). Revenue: ₹6.66b (up 19% from FY 2022). Net income: ₹530.9m (up ₹1.14b from FY 2022). Profit margin: 8.0% (up from net loss in FY 2022). Valuation Update With 7 Day Price Move • Jul 18
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹589, the stock trades at a trailing P/E ratio of 55.7x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 84% over the past year. Ankündigung • Jul 14
Orchid Pharma Limited, Annual General Meeting, Aug 09, 2023 Orchid Pharma Limited, Annual General Meeting, Aug 09, 2023, at 11:30 Indian Standard Time. Board Change • Jul 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. Additional Non-Executive & Independent Director Dharam Vir was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. New Risk • Jun 30
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 24% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (0.9x net interest cover). Minor Risks Large one-off items impacting financial results. Shareholders have been diluted in the past year (24% increase in shares outstanding). Reported Earnings • May 12
Full year 2023 earnings released: EPS: ₹13.01 (vs ₹14.80 loss in FY 2022) Full year 2023 results: EPS: ₹13.01 (up from ₹14.80 loss in FY 2022). Revenue: ₹6.85b (up 23% from FY 2022). Net income: ₹530.9m (up ₹1.14b from FY 2022). Profit margin: 7.7% (up from net loss in FY 2022). Reported Earnings • Feb 12
Third quarter 2023 earnings released: EPS: ₹1.86 (vs ₹2.59 loss in 3Q 2022) Third quarter 2023 results: EPS: ₹1.86 (up from ₹2.59 loss in 3Q 2022). Revenue: ₹1.60b (down 1.0% from 3Q 2022). Net income: ₹75.9m (up ₹181.6m from 3Q 2022). Profit margin: 4.7% (up from net loss in 3Q 2022). The move to profitability was driven by lower expenses. Ankündigung • Feb 02
Orchid Pharma Limited Announces Demise of Arun Kumar Dhanuka, Non-Executive & Non-Independent Director Orchid Pharma Limited announced demise of Arun Kumar Dhanuka, Non-Executive & Non-Independent Director on January 30, 2023. Reported Earnings • Nov 18
Second quarter 2023 earnings released Second quarter 2023 results: Revenue: ₹1.71b (up 34% from 2Q 2022). Net loss: ₹53.9m (loss narrowed 68% from 2Q 2022). Board Change • Nov 16
High number of new and inexperienced directors There are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. No experienced directors. No highly experienced directors. MD & Director Manish Dhanuka is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Ankündigung • Nov 15
Orchid Pharma Limited Announces Appointment of Marina Peter as Company Secretary and Compliance Officer Orchid Pharma Limited announced that Ms. Marina Peter an Associate Member of Institute of Company Secretaries of India, has been appointed as Company Secretary and Compliance Officer and has been further designated as Key Managerial Personnel of the Company with effect from November 14, 2022. Buying Opportunity • Oct 14
Now 21% undervalued Over the last 90 days, the stock is up 17%. The fair value is estimated to be ₹429, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 41% over the last year. Meanwhile, the company became loss making. Reported Earnings • Aug 11
First quarter 2023 earnings released: ₹3.68 loss per share (vs ₹6.93 loss in 1Q 2022) First quarter 2023 results: ₹3.68 loss per share (up from ₹6.93 loss in 1Q 2022). Revenue: ₹1.34b (up 45% from 1Q 2022). Net loss: ₹150.1m (loss narrowed 47% from 1Q 2022). Ankündigung • Aug 03
Orchid Pharma Limited to Report Q1, 2023 Results on Aug 10, 2022 Orchid Pharma Limited announced that they will report Q1, 2023 results on Aug 10, 2022 Ankündigung • Jul 23
Orchid Pharma Limited Announces Resignation of Nikita as Company Secretary and Compliance Officer Orchid Pharma Limited announced Nikita K has tendered resignation from the post of Company Secretary and Compliance officer Officer of the Company effective from 22 July 2022 Due to personal reasons. Reported Earnings • Jun 24
Full year 2022 earnings released Full year 2022 results: Revenue: ₹5.60b (up 24% from FY 2021). Net loss: ₹604.2m (loss narrowed 37% from FY 2021). Ankündigung • Jun 23
Orchid Pharma Limited, Annual General Meeting, Jul 15, 2022 Orchid Pharma Limited, Annual General Meeting, Jul 15, 2022, at 15:00 Indian Standard Time. Agenda: To receive, consider and adopt: the Audited Standalone Financial Statements of the Company for the financial year ended March 31, 2022; the Audited Consolidated Financial Statements of the Company for the financial year ended March 31, 2022; the Reports of the Board of Directors and Auditors thereon; to appoint a Director in place of Shri Ram Gopal Agarwal (DIN: 00627386) Chairman and Non-Executive Director of the Company, who retires by rotation and being eligible offers himself for re-appointment; to appoint Statutory Auditors of the Company and to fix their remuneration; and to consider other matters. Reported Earnings • May 19
Full year 2022 earnings released: ₹0.48 loss per share (vs ₹23.34 loss in FY 2021) Full year 2022 results: ₹0.48 loss per share (up from ₹23.34 loss in FY 2021). Revenue: ₹5.69b (up 26% from FY 2021). Net loss: ₹604.2m (loss narrowed 37% from FY 2021). Ankündigung • May 07
Orchid Pharma Limited to Report Q4, 2022 Results on May 12, 2022 Orchid Pharma Limited announced that they will report Q4, 2022 results on May 12, 2022 Board Change • Apr 27
High number of new and inexperienced directors There are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. No experienced directors. No highly experienced directors. MD & Director Manish Dhanuka is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Reported Earnings • Feb 15
Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint Third quarter 2022 results: ₹2.59 loss per share (up from ₹10.96 loss in 3Q 2021). Revenue: ₹1.61b (up 57% from 3Q 2021). Net loss: ₹105.7m (loss narrowed 76% from 3Q 2021). Revenue missed analyst estimates by 100%. Reported Earnings • Feb 11
Third quarter 2021 earnings released: ₹10.96 loss per share (vs ₹959 loss in 3Q 2020) The company reported a poor third quarter result with increased losses, weaker revenues and weaker control over costs. Third quarter 2021 results: Revenue: ₹1.03b (down 7.8% from 3Q 2020). Net loss: ₹447.2m (loss widened 15% from 3Q 2020). 
